JP6461901B2 - ネコ科苦味受容体及び方法 - Google Patents
ネコ科苦味受容体及び方法 Download PDFInfo
- Publication number
- JP6461901B2 JP6461901B2 JP2016500723A JP2016500723A JP6461901B2 JP 6461901 B2 JP6461901 B2 JP 6461901B2 JP 2016500723 A JP2016500723 A JP 2016500723A JP 2016500723 A JP2016500723 A JP 2016500723A JP 6461901 B2 JP6461901 B2 JP 6461901B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- tas2r
- receptor
- feline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000282324 Felis Species 0.000 title claims description 190
- 238000000034 method Methods 0.000 title claims description 131
- 108091005708 gustatory receptors Proteins 0.000 title description 294
- 235000019658 bitter taste Nutrition 0.000 title description 43
- 239000000203 mixture Substances 0.000 claims description 271
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 258
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 247
- 229920001184 polypeptide Polymers 0.000 claims description 245
- 150000001875 compounds Chemical class 0.000 claims description 210
- 210000004027 cell Anatomy 0.000 claims description 177
- 125000003729 nucleotide group Chemical group 0.000 claims description 91
- 239000002773 nucleotide Substances 0.000 claims description 90
- 238000012360 testing method Methods 0.000 claims description 87
- 238000009739 binding Methods 0.000 claims description 84
- 102000040430 polynucleotide Human genes 0.000 claims description 83
- 108091033319 polynucleotide Proteins 0.000 claims description 83
- 239000002157 polynucleotide Substances 0.000 claims description 83
- 230000027455 binding Effects 0.000 claims description 82
- 239000003446 ligand Substances 0.000 claims description 75
- 235000013305 food Nutrition 0.000 claims description 61
- 238000003556 assay Methods 0.000 claims description 51
- 230000004044 response Effects 0.000 claims description 35
- 239000013604 expression vector Substances 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 22
- 230000000295 complement effect Effects 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 19
- 230000003993 interaction Effects 0.000 claims description 18
- 210000004899 c-terminal region Anatomy 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 241000282326 Felis catus Species 0.000 claims description 8
- 241000251468 Actinopterygii Species 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 101100098799 Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) TAS2 gene Proteins 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 description 225
- 150000001413 amino acids Chemical class 0.000 description 224
- 102000005962 receptors Human genes 0.000 description 126
- 108020003175 receptors Proteins 0.000 description 126
- 108090000623 proteins and genes Proteins 0.000 description 103
- 239000000796 flavoring agent Substances 0.000 description 92
- 235000019634 flavors Nutrition 0.000 description 86
- 235000019640 taste Nutrition 0.000 description 75
- 239000000556 agonist Substances 0.000 description 70
- 241001465754 Metazoa Species 0.000 description 67
- 102000004169 proteins and genes Human genes 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 59
- 150000007523 nucleic acids Chemical class 0.000 description 52
- 230000000694 effects Effects 0.000 description 51
- 239000005557 antagonist Substances 0.000 description 47
- 102000039446 nucleic acids Human genes 0.000 description 39
- 108020004707 nucleic acids Proteins 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 36
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 28
- 230000003834 intracellular effect Effects 0.000 description 28
- 108020004705 Codon Proteins 0.000 description 26
- 230000008859 change Effects 0.000 description 26
- 239000013615 primer Substances 0.000 description 26
- 241000282414 Homo sapiens Species 0.000 description 23
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 23
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 22
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 108091006027 G proteins Proteins 0.000 description 20
- 102000030782 GTP binding Human genes 0.000 description 20
- 108091000058 GTP-Binding Proteins 0.000 description 20
- 101000787850 Homo sapiens Taste receptor type 2 member 38 Proteins 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- 102100025867 Taste receptor type 2 member 38 Human genes 0.000 description 18
- 238000013518 transcription Methods 0.000 description 18
- 230000035897 transcription Effects 0.000 description 18
- 239000011575 calcium Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 241000894007 species Species 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 239000003623 enhancer Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 229910052791 calcium Inorganic materials 0.000 description 15
- MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 14
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 14
- MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 14
- 241000282412 Homo Species 0.000 description 14
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 14
- AFHJQYHRLPMKHU-WEZNYRQKSA-N aloin B Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-WEZNYRQKSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 14
- -1 PLCβ2 Proteins 0.000 description 13
- 241000700584 Simplexvirus Species 0.000 description 13
- 210000000170 cell membrane Anatomy 0.000 description 13
- VWTINHYPRWEBQY-UHFFFAOYSA-N denatonium Chemical group [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 13
- 229940006275 denatonium Drugs 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 13
- 241000282465 Canis Species 0.000 description 12
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 12
- 230000001086 cytosolic effect Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000002940 repellent Effects 0.000 description 12
- 239000005871 repellent Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 235000015872 dietary supplement Nutrition 0.000 description 11
- 238000002955 isolation Methods 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical group CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 10
- 229960003081 probenecid Drugs 0.000 description 10
- 102100039215 Guanine nucleotide-binding protein G(t) subunit alpha-3 Human genes 0.000 description 9
- 241000283984 Rodentia Species 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000005540 biological transmission Effects 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000003527 eukaryotic cell Anatomy 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 108010005995 gustducin Proteins 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 230000014860 sensory perception of taste Effects 0.000 description 9
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 8
- FCSHMCFRCYZTRQ-UHFFFAOYSA-N N,N'-diphenylthiourea Chemical compound C=1C=CC=CC=1NC(=S)NC1=CC=CC=C1 FCSHMCFRCYZTRQ-UHFFFAOYSA-N 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- OGAKLTJNUQRZJU-UHFFFAOYSA-N diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 7
- 229960003520 diphenidol Drugs 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000006072 paste Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 235000001258 Cinchona calisaya Nutrition 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 108700010070 Codon Usage Proteins 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 101000626629 Homo sapiens Taste receptor type 2 member 4 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102100024854 Taste receptor type 2 member 4 Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229960000948 quinine Drugs 0.000 description 6
- 210000003370 receptor cell Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000011888 snacks Nutrition 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 101000892439 Homo sapiens Taste receptor type 2 member 10 Proteins 0.000 description 5
- 101000715025 Homo sapiens Taste receptor type 2 member 9 Proteins 0.000 description 5
- 102100040649 Taste receptor type 2 member 10 Human genes 0.000 description 5
- 102100036711 Taste receptor type 2 member 9 Human genes 0.000 description 5
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 235000019264 food flavour enhancer Nutrition 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000000099 in vitro assay Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000018 receptor agonist Substances 0.000 description 5
- 229940044601 receptor agonist Drugs 0.000 description 5
- 229940044551 receptor antagonist Drugs 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108010063331 type 2 taste receptors Proteins 0.000 description 5
- 101800001982 Cholecystokinin Proteins 0.000 description 4
- 102100025841 Cholecystokinin Human genes 0.000 description 4
- 241000255601 Drosophila melanogaster Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000626659 Homo sapiens Taste receptor type 2 member 1 Proteins 0.000 description 4
- 101000626662 Homo sapiens Taste receptor type 2 member 3 Proteins 0.000 description 4
- 101000787841 Homo sapiens Taste receptor type 2 member 31 Proteins 0.000 description 4
- 101000838273 Homo sapiens Taste receptor type 2 member 43 Proteins 0.000 description 4
- 101000652668 Homo sapiens Taste receptor type 2 member 7 Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 4
- 102100024845 Taste receptor type 2 member 1 Human genes 0.000 description 4
- 102100024842 Taste receptor type 2 member 3 Human genes 0.000 description 4
- 102100025866 Taste receptor type 2 member 31 Human genes 0.000 description 4
- 102100029031 Taste receptor type 2 member 43 Human genes 0.000 description 4
- 102100030842 Taste receptor type 2 member 7 Human genes 0.000 description 4
- 102000014384 Type C Phospholipases Human genes 0.000 description 4
- 108010079194 Type C Phospholipases Proteins 0.000 description 4
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 4
- 229960003291 chlorphenamine Drugs 0.000 description 4
- 229940107137 cholecystokinin Drugs 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 4
- 229940069510 parthenolide Drugs 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- 229940081974 saccharin Drugs 0.000 description 4
- 235000019204 saccharin Nutrition 0.000 description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960000317 yohimbine Drugs 0.000 description 4
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 4
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical group O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 3
- 102100040756 Rhodopsin Human genes 0.000 description 3
- 108090000820 Rhodopsin Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 235000019611 bitter taste sensations Nutrition 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000003269 fluorescent indicator Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000670 ligand binding assay Methods 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 229960002662 propylthiouracil Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000030812 sensory perception of bitter taste Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000036327 taste response Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000003901 trigeminal nerve Anatomy 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DBOVHQOUSDWAPQ-UHFFFAOYSA-N (4aS)-6c-[O2-(3,5,3'-trihydroxy-biphenyl-2-carbonyl)-beta-D-glucopyranosyloxy]-5t-vinyl-(4ar)-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-1-one Natural products OC1C(O)C(CO)OC(OC2C(C3C(C(OCC3)=O)=CO2)C=C)C1OC(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- BZXINCMCFVKGKB-UHFFFAOYSA-N Amarogentin Natural products OCC1OC(OC2OC=C3C(CCOC3=O)C2C=C)C(OC(=O)c4cc(O)cc(O)c4c5cccc(O)c5)C(O)C1O BZXINCMCFVKGKB-UHFFFAOYSA-N 0.000 description 2
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- ZOWKQQIGQBVKSV-BZLLESMPSA-N Cascarillin Chemical compound C=1([C@H](O)C[C@@]2([C@@H]3[C@@]([C@@]([C@H](O)CC3)(C)O)(C)C[C@H]([C@H]2C)OC(C)=O)C=O)C=COC=1 ZOWKQQIGQBVKSV-BZLLESMPSA-N 0.000 description 2
- GZVVOAJUBYETCL-UHFFFAOYSA-N Cascarillin Natural products CC1C(OC(C)=O)CC(C(C(O)CC2)(C)O)(C)C2C1(C(O1)O)CC1C=1C=COC=1 GZVVOAJUBYETCL-UHFFFAOYSA-N 0.000 description 2
- QPRMGHKASRLPJP-KZNAEPCWSA-N Cassine Natural products C[C@H]1N[C@H](CCCCCCCCCCC(C)=O)CC[C@H]1O QPRMGHKASRLPJP-KZNAEPCWSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 2
- RMFGNMMNUZWCRZ-UHFFFAOYSA-N Humulone Natural products CC(C)CC(=O)C1=C(O)C(O)(CC=C(C)C)C(O)=C(CC=C(C)C)C1=O RMFGNMMNUZWCRZ-UHFFFAOYSA-N 0.000 description 2
- 244000036274 Ilex cassine Species 0.000 description 2
- 235000002708 Ilex cassine Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000030555 Pygmy Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000011096 Somatostatin receptor Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- DBOVHQOUSDWAPQ-WTONXPSSSA-N amarogentin Chemical compound O([C@H]1[C@H](O[C@H]2[C@@H]([C@H]3C(C(OCC3)=O)=CO2)C=C)O[C@@H]([C@H]([C@@H]1O)O)CO)C(=O)C1=C(O)C=C(O)C=C1C1=CC=CC(O)=C1 DBOVHQOUSDWAPQ-WTONXPSSSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 239000013602 bacteriophage vector Substances 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000000723 chemosensory effect Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 229960000860 dapsone Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- KVFIJIWMDBAGDP-UHFFFAOYSA-N ethylpyrazine Chemical compound CCC1=CN=CC=N1 KVFIJIWMDBAGDP-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 famotidine Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013332 fish product Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- VMSLCPKYRPDHLN-NRFANRHFSA-N humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@@](O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-NRFANRHFSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000013554 lipid monolayer Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000031852 maintenance of location in cell Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- PIMZUZSSNYHVCU-YKWPQBAZSA-N picrotoxinin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2 PIMZUZSSNYHVCU-YKWPQBAZSA-N 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 102200006118 rs760640852 Human genes 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
- 238000003746 solid phase reaction Methods 0.000 description 2
- 238000010671 solid-state reaction Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009967 tasteless effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 235000019583 umami taste Nutrition 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NDYMQXYDSVBNLL-LAMASETHSA-N (23E)-25-acetyloxy-2,16alpha,20-trihydroxy-9beta-methyl-19-nor-10alpha-lanosta-1,5,23-triene-3,11,22-trione Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)C=CC(C)(C)OC(=O)C)C=C2[C@H]1C=C(O)C(=O)C2(C)C NDYMQXYDSVBNLL-LAMASETHSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- IXQKXEUSCPEQRD-NRNCYQGDSA-N (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)C=CC(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)C(=O)C2(C)C IXQKXEUSCPEQRD-NRNCYQGDSA-N 0.000 description 1
- KKXFYHZSOIALRM-XOBRGWDASA-N (4R,5R)-3,4-dihydroxy-5-(3-methylbut-2-enyl)-4-(4-methylpent-3-enoyl)-2-(2-methylpropanoyl)cyclopent-2-en-1-one Chemical compound CC(C)C(=O)C1=C(O)[C@@](O)(C(=O)CC=C(C)C)[C@@H](CC=C(C)C)C1=O KKXFYHZSOIALRM-XOBRGWDASA-N 0.000 description 1
- KKXFYHZSOIALRM-VLIAUNLRSA-N (4r,5s)-3,4-dihydroxy-5-(3-methylbut-2-enyl)-4-(4-methylpent-3-enoyl)-2-(2-methylpropanoyl)cyclopent-2-en-1-one Chemical compound CC(C)C(=O)C1=C(O)[C@@](O)(C(=O)CC=C(C)C)[C@H](CC=C(C)C)C1=O KKXFYHZSOIALRM-VLIAUNLRSA-N 0.000 description 1
- QARXXMMQVDCYGZ-QVKFZJNVSA-N (4s,5s)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbut-2-enyl)-4-(4-methylpent-3-enoyl)cyclopent-2-en-1-one Chemical compound CC(C)CC(=O)C1=C(O)[C@](O)(C(=O)CC=C(C)C)[C@H](CC=C(C)C)C1=O QARXXMMQVDCYGZ-QVKFZJNVSA-N 0.000 description 1
- LDXMPKMQIKGJFN-OKKPIIHCSA-N (6r)-3,5,6-trihydroxy-2-(2-methylbutanoyl)-4,6-bis(3-methylbut-2-enyl)cyclohexa-2,4-dien-1-one Chemical compound CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@](O)(CC=C(C)C)C1=O LDXMPKMQIKGJFN-OKKPIIHCSA-N 0.000 description 1
- NDYMQXYDSVBNLL-UHFFFAOYSA-N (9beta,10alpha,16alpha,23E)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)C=CC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C NDYMQXYDSVBNLL-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- PHZOWSSBXJXFOR-UHFFFAOYSA-N 2-Propenyl glucosinolate Natural products OCC1OC(SC(CC=C)=NOS(O)(=O)=O)C(O)C(O)C1O PHZOWSSBXJXFOR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241001455214 Acinonyx jubatus Species 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- LDXMPKMQIKGJFN-SPLOXXLWSA-N Adhumulone Natural products O=C([C@@H](CC)C)C=1C(=O)[C@@](O)(C/C=C(\C)/C)C(O)=C(C/C=C(\C)/C)C=1O LDXMPKMQIKGJFN-SPLOXXLWSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229910021532 Calcite Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- DRSITEVYZGOOQG-HXUWFJFHSA-N Cohumulone Natural products CC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)[C@](O)(CC=C(C)C)C1=O DRSITEVYZGOOQG-HXUWFJFHSA-N 0.000 description 1
- DRSITEVYZGOOQG-UHFFFAOYSA-N Cohumulone Chemical compound CC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O DRSITEVYZGOOQG-UHFFFAOYSA-N 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- IHTCCHVMPGDDSL-ZJNDIJRCSA-N Cucurbitacin A Natural products O=C([C@@](O)(C)[C@H]1[C@@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(CO)[C@H]2CC=C2C(C)(C)C(=O)[C@H](O)C[C@@H]12)/C=C/C(OC(=O)C)(C)C IHTCCHVMPGDDSL-ZJNDIJRCSA-N 0.000 description 1
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 1
- 108010036281 Cyclic Nucleotide-Gated Cation Channels Proteins 0.000 description 1
- 102000012003 Cyclic Nucleotide-Gated Cation Channels Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- QZJJDOYZVRUEDY-UHFFFAOYSA-N Dihydrocucurbitacin B Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(=O)C1(C)C QZJJDOYZVRUEDY-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- PDQAZBWRQCGBEV-UHFFFAOYSA-N Ethylenethiourea Chemical compound S=C1NCCN1 PDQAZBWRQCGBEV-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 241000282327 Felis silvestris Species 0.000 description 1
- 108091006099 G alpha subunit Proteins 0.000 description 1
- 102000034353 G alpha subunit Human genes 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- YGMIBVIKXJJQQJ-MSOSQAFRSA-N Grosshemin Chemical compound O[C@H]1CC(=C)[C@@H]2CC(=O)[C@@H](C)[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 YGMIBVIKXJJQQJ-MSOSQAFRSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 101000600912 Homo sapiens Substance-K receptor Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241001455213 Leopardus pardalis Species 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- IPCRBOOJBPETMF-UHFFFAOYSA-N N-acetylthiourea Chemical compound CC(=O)NC(N)=S IPCRBOOJBPETMF-UHFFFAOYSA-N 0.000 description 1
- GMEHFXXZSWDEDB-UHFFFAOYSA-N N-ethylthiourea Chemical compound CCNC(N)=S GMEHFXXZSWDEDB-UHFFFAOYSA-N 0.000 description 1
- XGEGHDBEHXKFPX-UHFFFAOYSA-N N-methylthiourea Natural products CNC(N)=O XGEGHDBEHXKFPX-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 241000601288 Panthera leo atrox Species 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000007074 Phospholipase C beta Human genes 0.000 description 1
- 108010047834 Phospholipase C beta Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000282374 Puma concolor Species 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- PHZOWSSBXJXFOR-MYMDCHNCSA-N Sinigrin Natural products S(=O)(=O)(O/N=C(\S[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)/CC=C)O PHZOWSSBXJXFOR-MYMDCHNCSA-N 0.000 description 1
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 1
- 101710142157 Stanniocalcin-1 Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 102000045879 Taste receptor type 2 Human genes 0.000 description 1
- 108091005711 Taste receptors type 2 (bitter) Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 239000012637 allosteric effector Substances 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- UDIUIXIBBPOQKL-UHFFFAOYSA-N aziridine-1-carbothioamide Chemical compound NC(=S)N1CC1 UDIUIXIBBPOQKL-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-N calcium;phosphoric acid Chemical compound [Ca+2].OP(O)(O)=O.OP(O)(O)=O YYRMJZQKEFZXMX-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 229910052799 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 229940095710 chewable product Drugs 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- IVGSDBLLLAUYTL-UHFFFAOYSA-N cucurbitacin E Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C=C(O)C(=O)C4(C)C)C3(C)CCC12C IVGSDBLLLAUYTL-UHFFFAOYSA-N 0.000 description 1
- 150000001904 cucurbitacins Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000021095 detection of chemical stimulus involved in sensory perception of bitter taste Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000010459 dolomite Substances 0.000 description 1
- 229910000514 dolomite Inorganic materials 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- QWCNQXNAFCBLLV-RCQSYPNMSA-N falcarindiol Chemical compound CCCCCCC\C=C/[C@H](O)C#CC#C[C@@H](O)C=C QWCNQXNAFCBLLV-RCQSYPNMSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- YGMIBVIKXJJQQJ-UHFFFAOYSA-N grosshemin guaianolide Natural products OC1CC(=C)C2CC(=O)C(C)C2C2OC(=O)C(=C)C21 YGMIBVIKXJJQQJ-UHFFFAOYSA-N 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- BGOFCVIGEYGEOF-UJPOAAIJSA-N helicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UJPOAAIJSA-N 0.000 description 1
- 229940068628 helicin Drugs 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- SKECXRFZFFAANN-UHFFFAOYSA-N n,n-dimethylmethanethioamide Chemical compound CN(C)C=S SKECXRFZFFAANN-UHFFFAOYSA-N 0.000 description 1
- 229940126662 negative allosteric modulator Drugs 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 108091008880 orphan GPCRs Proteins 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- IZJDOKYDEWTZSO-UHFFFAOYSA-N phenethyl isothiocyanate Chemical compound S=C=NCCC1=CC=CC=C1 IZJDOKYDEWTZSO-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229940126027 positive allosteric modulator Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- QKFAFSGJTMHRRY-OCFLFPRFSA-M potassium;[(e)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanylbut-3-enylideneamino] sulfate Chemical compound [K+].OC[C@H]1O[C@@H](S\C(CC=C)=N\OS([O-])(=O)=O)[C@H](O)[C@@H](O)[C@@H]1O QKFAFSGJTMHRRY-OCFLFPRFSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 102200141359 rs713598 Human genes 0.000 description 1
- BGOFCVIGEYGEOF-UHFFFAOYSA-N salicylaldehyde beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000017291 sinigrin Nutrition 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 235000021058 soft food Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000002426 superphosphate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/86—Addition of bitterness inhibitors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Description
一実施形態において、単離されたネコ科TAS2R(fTAS2R)受容体ポリペプチドは、ネコ科TAS2R受容体の細胞外ドメイン;ネコ科TAS2R受容体の膜貫通領域、又はネコ科TAS2R受容体の細胞内ドメインを含み、該fTAS2R受容体は、配列番号18、配列番号2、配列番号4、配列番号6、配列番号8、配列番号10、配列番号12、配列番号14、配列番号16、配列番号20、配列番号22、配列番号24、及び配列番号26から選択された配列を含み、単離されたfTAS2R受容体ポリペプチドは、配列番号2、4、6、又は10のアミノ酸配列からなるものではない。
一実施形態において、該ポリヌクレオチドは、配列番号7、配列番号9、配列番号11、配列番号13、配列番号15、配列番号17、配列番号19、配列番号21、配列番号23、又は配列番号25のヌクレオチド配列;配列番号8、配列番号12、配列番号14、配列番号16、配列番号18、配列番号20、配列番号22、配列番号24、又は配列番号26のアミノ酸配列をコードするヌクレオチド配列;配列番号7、配列番号9、配列番号11、配列番号13、配列番号15、配列番号17、配列番号19、配列番号21、配列番号23、又は配列番号25を有するポリヌクレオチドの相補体に高ストリンジェンシー条件下でハイブリダイズするヌクレオチド配列;及び先述のヌクレオチド配列の相補体、から選択されたヌクレオチド配列を含む。
fTAS2R受容体を検出するための抗体及びキットも開示される。
一実施形態において、該方法は、本明細書中のTAS2R受容体ポリペプチドを試験化合物と接触させること、及び該受容体ポリペプチドと試験化合物との間の相互作用を検出することを含む。
一実施形態において、可食組成物を調製する方法は、可食組成物又はその構成要素を、ネコ科TAS2R受容体ポリペプチドと、該可食組成物又はその構成要素に由来する苦味化合物の量を低減するのに十分な時間、接触させることを含む。
一実施形態において、香味組成物は、ネコ科TAS2R受容体ポリペプチドのアゴニスト又はアンタゴニストであって、該アゴニストはデナトニウム、アロイン、又はPTCであり、該アンタゴニストはプロベネシドである、アゴニスト又はアンタゴニストと;任意選択で食味増強剤と;任意選択で、可食組成物に香味組成物を付着させるのを支援する化合物と;任意選択で、色又は芳香を提供するための化合物とを含み、香味組成物は液体、固体、粉体、ペースト、ゲル、スプレッド調合物、顆粒、又は噴霧用調合物である。
一群の新規なネコ科苦味受容体である、ネコ科TAS2R(fTAS2R)が本明細書中に開示される。これらのGタンパク質共役型受容体(GPCR)は、ネコ科味覚伝達経路、具体的には苦味伝達経路の一部の構成要素であり、6‐n‐プロピルチオウラシル、オクタアセチルスクロース、ウンデカ酢酸ラフィノース、シクロヘキシミド、デナトニウム、グリシン銅、及びキニーネのような苦味物質のネコ科動物による味検出に関与する。新規なネコ科苦味受容体をコードするポリヌクレオチドも、新規なネコ科苦味受容体の発現のための発現ベクター及び宿主細胞も開示される。核酸及びコードされたポリペプチドを発現及び単離する方法も開示される。
「細胞質ドメイン」又は「細胞内ドメイン」は、細胞の内部に面するTAS2Rタンパク質のドメイン、例えば「C末端ドメイン」、並びに膜貫通ドメインの細胞内ループ、例えば膜貫通領域1及び2の間の細胞内ループ、膜貫通領域3及び4の間の細胞内ループ、並びに膜貫通領域5及び6の間の細胞内ループを指す。
一般に、「同一性」は、2つのポリヌクレオチド配列又はポリペプチド配列の、それぞれ正確なヌクレオチド対ヌクレオチドの一致又はアミノ酸対アミノ酸の一致を指す。
本明細書中で互換的に使用される、用語「単離された」又は「精製された」は、核酸、ポリペプチド、又はその他の生体構成部分であって、天然において関連している構成要素から取り出されているものを指す。用語「単離された」は、ポリペプチドであって、該分子が自然界においてともに見出される生物体全体から分離しておりかつ別個であるか、又は同じ種類の他の生体高分子がほぼ存在しない状態で存在しているものを指すことができる。ポリヌクレオチドに関しての用語「単離された」は、核酸分子であって、自然界において該核酸分子に通常関連している配列を全部若しくは部分的に欠いているもの;又は自然界に存在するとおりの配列であるが、該配列に関連する異種配列を有するもの;又は染色体との関係から切り離された分子を指す場合がある。純度及び均質性は、典型的には、分析化学技法、例えばポリアクリルアミドゲル電気泳動法又は高速液体クロマトグラフィーを使用して決定される。調製物中に存在する優勢な分子種であるタンパク質が実質的に精製される。特に、単離されたTAS2R核酸は、TAS2R遺伝子に隣接してTAS2R以外のタンパク質をコードするオープンリーディングフレームから分離される。いくつかの実施形態では、用語「精製された」は、核酸又はタンパク質が少なくとも85%の純度、具体的には少なくとも90%の純度、より具体的には少なくとも95%の純度、又はさらにより具体的には少なくとも99%の純度であることを意味する。
用語「核酸」、「ポリヌクレオチド」、又は「オリゴヌクレオチド」は、DNA分子及びRNA分子を含む。ポリヌクレオチドは一本鎖であってもよいし、二本鎖であってもよい。ポリヌクレオチドは、合成、天然型、及び非天然型の、既知のヌクレオチドアナログ又は改変された主鎖の残基若しくは結合であって、基準の核酸と同様の結合特性を有するものを含有することが可能である。そのようなアナログの例には、限定するものではないが、ホスホロチオアート、ホスホロアミダート、メチルホスホン酸、キラル‐メチルホスホン酸、2‐O‐メチルリボヌクレオチド、ペプチド核酸(PNA)が挙げられる。ポリヌクレオチドは、当分野で既知の適切な方法、例えば天然供給源からの単離、化学合成、又は酵素的合成によって得ることが可能である。ヌクレオチドはその一般に容認された1文字コードによって参照されうる。
リガンドの結合又は受容体活性を測定するための本明細書中に記載されたアッセイにおいて使用される「TAS2R受容体ポリペプチド」(又はTAS2R受容体若しくはTAS2R)は、TAS2R受容体;TAS2R受容体のドメイン、例えば細胞外ドメイン、膜貫通領域、膜貫通ドメイン、細胞質ドメイン、リガンド結合フラグメント、サブユニット会合ドメイン、活性部位など;又は、TAS2R受容体若しくはそのドメインのいずれかが異種タンパク質に共有結合で連結されているキメラタンパク質を含むことができる。
本明細書中で使用されるような用語「味知覚(taste perception)」は、味覚刺激に対するTAS2R受容体の応答(例えば、生化学的応答、行動反応)又は感受性を指す。味知覚の改変には、味物質に応答した哺乳類の生化学的応答、食物摂取行動、味の優先傾向、代謝応答、又は一般行動の変更(増強、低減、若しくは変化)が挙げられる。「味知覚」は、哺乳類によるin vivoの味の感覚をもたらす神経シグナルの伝送を必要とはしないが、含むことはできる。
一実施形態において、単離されたfTAS2Rポリペプチドは、本明細書中に開示されたポリヌクレオチドによってコードされている。
さらに開示されるのは、本明細書中に開示された少なくとも2個のfTAS2Rポリペプチドを含む組成物である。一実施形態において、組成物は本明細書中に開示された少なくとも3、4、又は5個のポリペプチドを含む。一実施形態において、組成物は本明細書中に開示された少なくとも6、7、8、9、10、11、12、又は13個のポリペプチドを含む。一実施形態において、組成物中のポリペプチドはそれぞれ異なるfTAS2R受容体である。一実施形態において、組成物は、配列番号18を含むポリペプチドと配列番号22を含むポリペプチドとを含む。
一実施形態において、該方法は、TAS2R受容体を、TAS2R受容体に結合する疑いのある試験化合物と接触させること;及び、該化合物とTAS2R受容体との間の結合を検出することを含む。結合は、当業者に知られた任意の結合アッセイ、例えばゲルシフトアッセイ、ウエスタンブロット、放射性標識競合アッセイ、ファージを用いる発現クローニング、クロマトグラフィーによる共分画(co−fractionation)、共沈、架橋結合、相互作用トラップ/ツーハイブリッド分析、サウスウエスタン分析、及びELISAなどによって判定可能である。方法はさらに、標識、例えば放射性標識(例えば125I、35S、32P、33P、3H)、蛍光標識、化学発光標識、酵素標識、及び免疫原性標識などに取り付けられたリガンドを使用する場合もある。1つの変法では、表面にTAS2R受容体を発現している細胞を含む組成物が、該方法において使用される。別の変法では、単離されたTAS2R受容体又はTAS2R受容体を含む細胞膜が使用される。結合は、例えば標識化合物の使用によって直接測定されてもよいし、間接的に測定されてもよい。TAS2R受容体に結合するとして同定された化合物は、その活性を確認又は定量するために、TAS2R活性アッセイ及び/又はin vivoのモデルを含む他のアッセイにおいてさらに試験されてもよい。
モノクローナル又はポリクローナルの抗fTAS2R抗体の調製については、当分野で既知の任意の技法が使用可能である。一本鎖抗体を生産するための技法(米国特許第4,946,778号明細書)を、本明細書中に開示されたポリペプチドに対する抗体を生産するように適合させることも可能である。さらに、遺伝子組換えマウス、又は他の哺乳類のような他の生物体が、ヒト化抗体を発現するために使用されてもよい。別例として、ファージディスプレイ技術を使用して、選択された抗原に特異的に結合する抗体及びヘテロ多量体Fabフラグメントを同定することが可能である。1つの実施形態では、モノクローナル抗体又はその結合性フラグメントをコードする単離されたDNA配列は、ヒューズ(Huse)ら、サイエンス(Science)、1989年、第246巻、p.1275−1281によって概説された一般的なプロトコールに従って、ヒトB細胞由来のDNAライブラリをスクリーニングすることにより得られる。
香味組成物は、動物により摂取されるように可食組成物の受容を改善するため、該動物用の可食組成物に加えることが可能な組成物である。可食組成物の例には、食物、おやつ、栄養補助食品、医薬品、デンタルケア製品のような口腔ケア材料、咀嚼用製品、飲用製品などが挙げられる。可食組成物は、タブレット、カプセル、カプレット、可食フィルム、ウェットフード、液状食物、おやつ又はキブルの形をとることが可能である。
一実施形態において、該方法は、ネコ科TAS2R受容体ポリペプチドのアゴニスト、アンタゴニスト、又はモジュレーターと;任意選択で食味増強剤と;任意選択で、可食組成物への香味組成物の付着を助ける化合物と;任意選択で、色又は芳香を提供するための化合物とを、食肉加工品、食肉副産物、魚加工品、魚副産物、乳製品、乳製品副産物、微生物タンパク質の供給源、植物性タンパク質、炭水化物及びアミノ酸の担体からなる群から選択された材料と混合して香味組成物を得ることを含み、該香味組成物は、液体、固体、粉体、ペースト、ゲル、スプレッド調合物、顆粒、又は噴霧用調合物である。一実施形態において、ネコ科TAS2R受容体ポリペプチドのアゴニスト又はアンタゴニストを組成物に混入させる。一実施形態において、アゴニストはデナトニウム、アロイン、又はPTCであり、アンタゴニストはプロベネシドである。
一実施形態において、該方法は、可食組成物又はその構成要素を、本明細書中に開示されたfTAS2R受容体ポリペプチドと、該可食組成物又はその構成要素から苦味化合物の量を低減するのに十分な時間、接触させることを含む。苦味化合物の量を低減する時間は、当業者によって決定可能である。接触は、連続的、半連続的、又はバッチ式のプロセスで行うことが可能である。一実施形態において、可食組成物はネコ科用である。
一実施形態において、該方法は、可食組成物中の、ネコ科TAS2R受容体ポリペプチドのアゴニスト、アンタゴニスト、又はモジュレーターである化合物の存在を決定すること;及び、可食組成物の食味を、化合物がアゴニスト若しくは正のモジュレーターである場合は可食組成物中の受容体アンタゴニストの量を増加させるか若しくは可食組成物中の化合物の量を低減することにより、又は化合物がアンタゴニスト若しくは負のモジュレーターである場合は可食組成物中の該化合物の量を増加させることにより、増強することを含む。該化合物を含む香味組成物を、香味組成物が可食組成物に組み込まれるか又は少なくとも部分的に可食組成物をコーティングするように可食組成物に適用することにより、該化合物の量を増加させることができる。
一実施形態において、該方法は、ネコ科用の食物組成物又はその構成要素を、本明細書中のTAS2R受容体ポリペプチドと、該食物製品又は構成要素から苦味化合物を取り除くのに十分な時間、接触させることを含む。一実施形態において、TAS2R受容体は、食物組成物から分離することが可能な固体担体に結合される。一実施形態において、接触は連続的な操作である。一実施形態において、食物組成物は複数のTAS2R受容体ポリペプチドと接触させられる。
実施例
実施例1.ネコ科苦味受容体(TAS2R)の遺伝子配列及びポリペプチド配列の決定
本実施例では、ネコ科TAS2R遺伝子が、ヒトの苦味受容体遺伝子配列を用いてNCBIのイエネコ(Felis catus)ホールゲノムショットガン法コンティグデータベースに検索要求することにより同定された。使用されたヒト遺伝子配列は、表2にNCBI遺伝子IDによって特定されている。
実施例2.ネコ科TAS2Rのための発現系
A.ネコ科TAS2Rのための発現ベクターの生成
本実施例は、代表的なネコ科苦味受容体であるTAS2R38のための発現ベクターの生成について説明する。TAS2R受容体それぞれについて類似のプロセスが行われる。
TAS2R38のcDNAを、プラスミド/発現ベクターpcDNA3.1D‐V5His(米国カリフォルニア州カールスバードのライフ・テクノロジーズ)を基にした発現カセットであって、そのマルチプルクローニングサイト内に受容体の表面検出を可能にするためのFLAGエピトープ、次に導入遺伝子の細胞表面標的化を容易にするためのラットのソマトスタチン受容体サブタイプ3の最初の45アミノ酸(RSSタグ)をコードするヌクレオチド配列、及びカルボキシ末端における免疫細胞化学的な検出を容易にするための単純ヘルペスウイルス(HSV)糖タンパク質Dエピトープ(HSVエピトープ)をコードするヌクレオチド配列(HSVタグ)を含有する発現カセットにサブクローニングした。
本明細書中に開示された他のfTAS2Rそれぞれのための発現ベクターの生成は、類似のステップによって実施された。
本明細書中に開示された所望のTAS2Rを一過性に発現する細胞株は、適当な発現ベクター、例えば実施例2Aで上述されたように構築されたpcDNA3.1D‐FLAGV5His‐TAS2R38を、真核細胞株(ライフ・テクノロジーズ、カタログ番号R700‐07)の細胞にトランスフェクションすることにより作製された。
作製された様々な細胞株におけるfTAS2Rの発現はフローサイトメトリーによって判断された。細胞外のFLAGタグは、フルオレセインイソチオシアネート(FITC)にコンジュゲートしたFLAG‐特異抗体で検出された。所与のfTAS2Rを発現する細胞の割合(%)は、FITCシグナルについて陽性の細胞の割合(%)によって決定された。fTAS2R発現のレベルは測定された蛍光強度の幾何平均によって決定された。発現されたfTAS2Rの各々についての結果は表8に示されている。
既知のhTAS2R38リガンドであるPTC及びPROPに対するfTAS2R38の機能的応答、並びに既知のhTAS2R43リガンドであるアロイン、デナトニウム及びサッカリン)に対するfTAS2R43の機能的応答についての試験は、Fluo‐4AM(ライフ・テクノロジーズ・コーポレイション)カルシウムアッセイを使用する自動カルシウムイメージングによって決定された。
fTAS2Rを安定して発現する細胞株も得られる。
これらの実験については、fTAS2R38のcDNAは、プラスミド/発現ベクターpcDNA3.1Zeo(米国カリフォルニア州カールスバードのライフ・テクノロジーズ)を基にした発現カセットであって、そのマルチプルクローニングサイト内に導入遺伝子の細胞表面標的化を容易にするためのラットのソマトスタチン受容体サブタイプ3の最初の45アミノ酸(RSSタグ)をコードするヌクレオチド配列、及び免疫細胞化学的な検出を容易にするための単純ヘルペスウイルス(HSV)糖タンパク質Dエピトープ(HSVエピトープ)をコードするヌクレオチド配列(HSVタグ)を含有する発現カセットにサブクローニングされる。
本明細書中に開示された他のfTAS2Rのための発現ベクターの生成も同様である。使用される制限酵素は適宜変更される。
fTAS2R38の発現は、Fluo‐4AM(ライフ・テクノロジーズ・コーポレイション)カルシウムアッセイを使用する自動カルシウムイメージングによって決定される、既知のhTAS2R38リガンド(例えばPTC及びPROP)に対する機能的応答の存在について試験することにより判断される。Fluo‐4AMは細胞内のカルシウム動特性(濃度の変化)の蛍光指示薬であり、カルシウム濃度の変化、特にアゴニストへの曝露後に生じる受容体活性化に応答した増大のモニタリングを可能にする。1つのクローンが選択され、その結果Gα16‐ガストデューシン44/TAS2R38細胞株が得られる。Gα16‐ガストデューシン44/TAS2R38細胞株は、100μMのPTCの存在下でベースラインよりも90%刺激されたが、30μmのPROPでは刺激されなかった。
実施例3.ネコ科TAS2Rのリガンド及びエフェクターのための細胞系スクリーニング
ネコ科TAS2R38受容体のアゴニスト、アンタゴニスト及びモジュレーターの同定は、ネコ科TAS2R38及びGα16gust44でトランスフェクションされた細胞に対する試験化合物の効果がトランスフェクションされていない細胞に対する試験化合物の効果と比較される、細胞系スクリーニングアッセイによって実施される。
実施例4.香味組成物及び忌避剤組成物
本明細書中に開示されたネコ科TAS2R受容体のアゴニスト、アンタゴニスト、又はモジュレーターを含む、例示的な動物用乾燥香味組成物は、一般に以下の組成で作製される。
ネコ科TAS2R受容体のアゴニスト、アンタゴニスト、又はモジュレーターを含む、例示的な動物用液体香味組成物は、一般に以下の組成で作製される。
ペットのネコが対象物を噛んだり食べたりするのを防止するために該対象物に噴霧するためのエアロゾルの形態の例示的な忌避剤組成物は、50%の有効成分溶液であって有効成分はネコ科TAS2Rアゴニスト又は正のモジュレーターである溶液を、50%の推進剤ガスであって例えばFrigen 11/12(ハロゲン化炭化水素)又はプロパン/ブタン(例えば15:85比)とともに、エアゾール缶の中で調合することにより作製される。有効成分溶液は、液体希釈剤(例えば水)に溶解された重量比で約0.5%〜約30%のネコ科TAS2Rアゴニスト又は正のモジュレーターと、任意選択で0.5〜1.5%の芳香薬又は香料と、最大29.5%のイソプロパノールとからなる。ネコ科TAS2Rアゴニストはデナトニウム、アロイン、又はPTCである。
実施形態5. 前記異種ポリペプチドはネコ科TAS2R受容体ポリペプチドのアミノ末端又はカルボキシ末端に連結されている、実施形態4のポリペプチド。
実施形態9. fTAS2R受容体活性を有するか、又はfTAS2R受容体のリガンドに結合する、実施形態1〜8のうちいずれか1つのポリペプチド。
実施形態11. fTAS2RはfTAS2R38であり、かつ配列番号18のアミノ酸74はNである、実施形態1〜10のうちいずれか1つのポリペプチド。
実施形態14. 実施形態1〜12のうちいずれか1つのポリペプチドをコードする、単離されたポリヌクレオチド。
実施形態18. 少なくとも25個の連続するヌクレオチドを含む、実施形態16又は17のポリヌクレオチド。
実施形態20. 前記非ネコ科細胞は、大腸菌(Escherichia coliE.)、出芽酵母細胞(Saccharomyces cerevisae cellyeast)、キイロショウジョウバエ(Drosophila melanogaster)の細胞、線虫(Caenorhabditis elegans)の細胞、又は哺乳類の細胞である、実施形態19のポリヌクレオチド。
実施形態22. 非天然物である、実施形態14〜21のうちいずれか1つのポリヌクレオチド。
実施形態24. ネコ科TAS2Rポリペプチドをコードする核酸の少なくとも一部分を増幅するためのプライマー対。
実施形態26. 実施形態14〜22のうちいずれか1つのポリヌクレオチドによってコードされているネコ科TAS2R受容体ポリペプチド。
実施形態28. 実施形態27の発現ベクターを含む宿主細胞。
実施形態30. 前記細胞は、ヒト、ネズミ科、又はネコ科の細胞である、実施形態28又は29の宿主細胞。
実施形態32. 実施形態28〜31のうちいずれか1つの細胞を少なくとも1個含む細胞培養物。
実施形態35. 少なくとも18個、最大で30個の連続するヌクレオチドを含む、実施形態33又は34のオリゴヌクレオチド。
実施形態37. ネコ科TAS2R受容体ポリペプチドと相互作用する化合物を同定する方法であって、実施形態1〜12及び26のうちいずれか1つのポリペプチドを試験化合物と接触させること、及び、前記ポリペプチドと試験化合物との間の相互作用を検出することを含む方法。
実施形態40. ネコ科TAS2R受容体ポリペプチドを変調する化合物を同定する方法であって、実施形態1〜12及び24のうちいずれか1つのポリペプチドを、別々のアッセイで試験化合物の存在下及び非存在下の両方においてTAS2R受容体リガンドと接触させること、及び、試験化合物が受容体ポリペプチドへのリガンドの結合又はリガンドによる受容体ポリペプチドの活性化を変調するかどうか判定することを含む方法。
実施形態43. 前記ポリペプチドは、固体担体に結合されるか、宿主細胞内、二重膜内、脂質単層内、又は小胞内で発現される、実施形態37〜42のうちいずれか1つの方法。
実施形態46. 前記接触は、連続操作、半連続操作、又はバッチ操作である、実施形態44又は45の方法。
実施形態51. 苦味化合物を、それを必要とする動物に与える方法であって、動物に可食組成物を与えることを含み、該可食組成物は、苦味化合物と、実施形態1〜12及び26のうちいずれか1つのネコ科TAS2R受容体ポリペプチドのアゴニスト、アンタゴニスト、又はモジュレーターである化合物であって、動物による可食組成物の受容を、該化合物を含まない可食組成物の受容と比較して変更する化合物とを含む、方法。
実施形態53. 動物に対する可食組成物の食味を制御するために可食組成物を調製する方法であって、動物に対する可食組成物の食味を低下させるために該可食組成物に化合物を添加することを含み、該化合物は実施形態1〜12及び26のうちいずれか1つのネコ科TAS2R受容体ポリペプチドのアゴニスト又は正のモジュレーターである、方法。
参照文献はすべて、参照により本願に組み込まれる。
Claims (17)
- 配列番号18、配列番号8、配列番号12、配列番号14、配列番号16、配列番号20、配列番号22、配列番号24、及び配列番号26のうちから選択された配列を含む単離されたネコ科TAS2R(fTAS2R)ポリペプチド。
- 異種ポリペプチドをさらに含む、請求項1に記載のポリペプチド。
- 前記異種ポリペプチドは前記ネコ科TAS2Rポリペプチドのアミノ末端又はカルボキシ末端に連結されている、請求項2に記載のポリペプチド。
- fTAS2Rポリペプチドは配列番号18又は配列番号22のアミノ酸配列を含む、請求項1〜3のいずれか一項に記載のポリペプチド。
- (a)請求項1〜3のいずれか一項に記載のポリペプチドをコードするポリヌクレオチド;
(b)ネコ科TAS2R(fTAS2R)ポリペプチド、又はそのフラグメントをコードするポリヌクレオチドであって、
配列番号17、配列番号7、配列番号11、配列番号13、配列番号15、配列番号19、配列番号21、配列番号23、又は配列番号25のヌクレオチド配列;
配列番号18、配列番号8、配列番号12、配列番号14、配列番号16、配列番号20、配列番号22、配列番号24、又は配列番号26のアミノ酸配列をコードするヌクレオチド配列;及び
上述した各ヌクレオチド配列の相補体
のうちから選択されたヌクレオチド配列を含むポリヌクレオチド
のうちから選択される、単離されたポリヌクレオチド。 - 請求項5に記載のポリヌクレオチドを含む発現ベクター。
- 請求項6に記載の発現ベクターを含む宿主細胞。
- 前記細胞は哺乳類細胞、魚類細胞、ヒト細胞、ネズミ科細胞、ネコ科細胞、酵母細胞、細菌細胞、又は昆虫細胞である、請求項7に記載の宿主細胞。
- ネコ科TAS2Rポリペプチドと相互作用する化合物を同定する方法であって、
請求項1〜4のいずれか一項に記載のポリペプチドを試験化合物と接触させること、及び
前記ポリペプチドと試験化合物との間の相互作用を検出すること
を含む方法。 - ネコ科TAS2Rポリペプチドの機能的応答を変調する化合物を同定する方法であって、
請求項1〜4のいずれか一項に記載のポリペプチドを、別々のアッセイで試験化合物の存在下及び非存在下の両方においてTAS2Rリガンドと接触させること、及び
試験化合物が前記ポリペプチドへのリガンドの結合又はリガンドによる前記ポリペプチドの活性化を変調するかどうか判定すること
を含む方法。 - 可食組成物を調製する方法であって、
可食組成物又はその構成要素を、配列番号18、配列番号8、配列番号12、配列番号14、配列番号16、配列番号20、配列番号22、配列番号24、及び配列番号26のうちから選択された配列を含む単離されたネコ科TAS2R(fTAS2R)ポリペプチドと、前記可食組成物又はその構成要素に由来する苦味化合物の量を低減するのに十分な時間、接触させることを含む方法。 - fTAS2Rポリペプチドが異種ポリペプチドをさらに含む、請求項11に記載の方法。
- 前記異種ポリペプチドはfTAS2Rポリペプチドのアミノ末端又はカルボキシ末端に連結されている、請求項12に記載の方法。
- fTAS2Rポリペプチドは前記可食組成物から分離することが可能な固体担体に結合されている、請求項11〜13のいずれか一項に記載の方法。
- 前記接触は、連続操作、半連続操作、又はバッチ操作である、請求項11〜14のいずれか一項に記載の方法。
- 前記可食組成物はネコ科用の食物組成物であり、前記組成物又はその構成要素は複数の異なるポリペプチドと接触させられる、請求項11〜15のいずれか一項に記載の方法。
- fTAS2Rポリペプチドは配列番号18又は配列番号22のアミノ酸配列を含む、請求項11〜16のいずれか一項に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361788528P | 2013-03-15 | 2013-03-15 | |
US61/788,528 | 2013-03-15 | ||
US201461945500P | 2014-02-27 | 2014-02-27 | |
US61/945,500 | 2014-02-27 | ||
PCT/US2014/021110 WO2014149829A1 (en) | 2013-03-15 | 2014-03-06 | Feline bitter taste receptors and methods |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016519649A JP2016519649A (ja) | 2016-07-07 |
JP2016519649A5 JP2016519649A5 (ja) | 2017-04-06 |
JP6461901B2 true JP6461901B2 (ja) | 2019-01-30 |
Family
ID=50391437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016500723A Active JP6461901B2 (ja) | 2013-03-15 | 2014-03-06 | ネコ科苦味受容体及び方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US9603379B2 (ja) |
EP (1) | EP2983507B1 (ja) |
JP (1) | JP6461901B2 (ja) |
AU (1) | AU2014237801B2 (ja) |
BR (1) | BR112015023737A2 (ja) |
CA (1) | CA2903208C (ja) |
ES (1) | ES2797547T3 (ja) |
MX (1) | MX2015013013A (ja) |
WO (1) | WO2014149829A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9169311B2 (en) | 2013-03-15 | 2015-10-27 | Applied Food Biotechnology, Inc. | Feline bitter taste receptors and methods |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
WO2022224061A1 (en) * | 2021-04-21 | 2022-10-27 | Societe Des Produits Nestle Sa | Methods of identifying modulators of receptors over-expressed in circumvallate taste papillae in animals such as cats, methods of using such modulators in food, and foods made by such methods |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5825980B2 (ja) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | サイクリックヌクレオチドの定量法 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
US6558910B2 (en) * | 1999-09-10 | 2003-05-06 | The Regents Of The University Of California | SF, a novel family of taste receptors |
CN1289525C (zh) | 1999-09-10 | 2006-12-13 | 加利福尼亚大学董事会 | T2r,一类味觉受体 |
WO2001077676A1 (en) | 2000-04-07 | 2001-10-18 | Senomyx, Inc. | T2r taste receptors and genes encoding same |
US7368285B2 (en) | 2001-03-07 | 2008-05-06 | Senomyx, Inc. | Heteromeric umami T1R1/T1R3 taste receptors and isolated cells that express same |
EP2267128A3 (en) | 2002-09-25 | 2011-08-10 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke | Bitter taste receptors |
CN1726224A (zh) | 2002-12-18 | 2006-01-25 | 吉万奥丹股份有限公司 | 嵌合αQ-Gustducin G-蛋白 |
ATE471335T1 (de) | 2002-12-23 | 2010-07-15 | Vical Inc | Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden |
WO2004069191A2 (en) | 2003-02-03 | 2004-08-19 | Senomyx Inc. | Identification of t1r and t2r modulators |
AU2004258071A1 (en) | 2003-06-19 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Variants of human taste receptor genes |
AU2004256023B2 (en) | 2003-06-27 | 2008-03-13 | Monell Chemical Senses Center | Taste receptors of the T1R family from domestic cat |
BRPI0413347A (pt) | 2003-08-06 | 2006-10-10 | Senomyx Inc | novos sabores, modificadores de sabor, agentes de sabor, realçadores de sabor, agentes de sabor e/ou realçadores umami ou doces, e utilização correspondente |
US7541158B2 (en) | 2004-04-14 | 2009-06-02 | Monell Chemical Senses Center | Taste receptors of the T1R family from domestic dog |
US7829299B2 (en) * | 2004-11-18 | 2010-11-09 | Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts | Agonists of bitter taste receptors and uses thereof |
AU2006213039A1 (en) | 2005-02-08 | 2006-08-17 | Senomyx, Inc. | Phuman T2R receptors for acetaminophen, ranitidine, strychnine and denatonium and related assays for identifying human bitter taste modulators |
EP1975611A1 (en) | 2007-03-29 | 2008-10-01 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Agonists of bitter taste receptors and uses thereof |
WO2008119195A1 (en) | 2007-03-30 | 2008-10-09 | Givaudan Sa | Methods to identify modulators |
EP1983342A1 (en) | 2007-04-18 | 2008-10-22 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Antogonists of bitter taste receptors and uses thereof |
EP2164976A4 (en) | 2007-06-08 | 2010-06-30 | Senomyx Inc | THEORETICAL BASIS, METHODS AND TESTS FOR IDENTIFYING FLAVOR SPECIES OF HUMAN AND NON-MUSCLE PRIMATES AND USE THEREOF IN TASTE MODULATOR AND THERAPEUTIC SCREENING TESTS |
EP2300830B1 (en) | 2008-06-13 | 2015-05-20 | Givaudan SA | Methods of identifying modulators of the bitter taste receptor tas2r44 |
EP2391711B1 (en) | 2009-02-02 | 2015-04-08 | Chromocell Corporation | Novel cell lines and methods |
EP2460010A1 (en) * | 2009-07-28 | 2012-06-06 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke | Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof |
WO2011050955A1 (en) * | 2009-10-27 | 2011-05-05 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Antagonists and agonists of bitter taste receptors and uses thereof |
CA2805702A1 (en) | 2010-07-27 | 2012-02-02 | Specialites Pet Food | Methods and compositions for stimulating a felidae t1r receptor |
US9169311B2 (en) | 2013-03-15 | 2015-10-27 | Applied Food Biotechnology, Inc. | Feline bitter taste receptors and methods |
-
2014
- 2014-03-06 MX MX2015013013A patent/MX2015013013A/es unknown
- 2014-03-06 AU AU2014237801A patent/AU2014237801B2/en active Active
- 2014-03-06 ES ES14714028T patent/ES2797547T3/es active Active
- 2014-03-06 EP EP14714028.9A patent/EP2983507B1/en active Active
- 2014-03-06 US US14/774,948 patent/US9603379B2/en active Active
- 2014-03-06 WO PCT/US2014/021110 patent/WO2014149829A1/en active Application Filing
- 2014-03-06 CA CA2903208A patent/CA2903208C/en active Active
- 2014-03-06 JP JP2016500723A patent/JP6461901B2/ja active Active
- 2014-03-06 BR BR112015023737A patent/BR112015023737A2/pt not_active IP Right Cessation
-
2017
- 2017-03-27 US US15/469,692 patent/US10174096B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014237801A1 (en) | 2015-08-27 |
US9603379B2 (en) | 2017-03-28 |
CA2903208C (en) | 2021-05-18 |
AU2014237801B2 (en) | 2017-08-10 |
JP2016519649A (ja) | 2016-07-07 |
US10174096B2 (en) | 2019-01-08 |
BR112015023737A2 (pt) | 2017-10-24 |
WO2014149829A1 (en) | 2014-09-25 |
US20170198022A1 (en) | 2017-07-13 |
MX2015013013A (es) | 2015-12-01 |
CA2903208A1 (en) | 2014-09-25 |
US20160015062A1 (en) | 2016-01-21 |
EP2983507B1 (en) | 2020-04-22 |
EP2983507A1 (en) | 2016-02-17 |
ES2797547T3 (es) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4339542B2 (ja) | T2r、すなわち味覚受容体の新規ファミリー | |
Foster et al. | Extrasensory perception: odorant and taste receptors beyond the nose and mouth | |
RU2146132C1 (ru) | Фармацевтическая композиция, активная в отношении рецептора кальция, способ лечения пациента, способ анализа соединения оказывать влияние на активность рецептора неорганического иона, нуклеиновая кислота, кодирующая рецептор, рецептор кальция | |
JP2009145349A (ja) | 新規な苦味受容体t2r76の同定 | |
TW200904981A (en) | Identification of TRPML3 (mcoln3) as a salty taste receptor and use in assays for identifying taste (salty) modulators and/or therapeutics that modulate sodium transport, absorption or excretion and/or aldosterone and/or vasopressin production or release | |
JP2001514879A (ja) | カプサイシン受容体およびカプサイシン受容体関連ポリペプチドをコードする核酸配列ならびにその使用 | |
KR20070053659A (ko) | 쓴맛 수용체의 작용제 및 그의 용도 | |
US20090226403A1 (en) | Olfactory and pheromones G-protein coupled receptors | |
US10473673B2 (en) | Methods for increasing palatability of pet foodstuff | |
US10174096B2 (en) | Feline bitter taste receptors and methods | |
US10295529B2 (en) | Feline bitter taste receptors and methods | |
Pernollet et al. | Structural Recognition Between Odorants, Olfactory‐Binding Proteins and Olfactory Receptors‐First Events in Odour Coding | |
CN101998989A (zh) | Trpml3(mcoln3)作为咸味受体的鉴定及在用于鉴定调控钠转运、吸收或排泄和/或醛固酮和/或血管加压素的产生或释放的味觉(咸味)调节剂和/或治疗剂的测定中的用途 | |
CA2406481A1 (en) | Trp8, a transient receptor potential channel expressed in taste receptor cells | |
US20070059688A1 (en) | Gastrointestinal chemosensory receptors | |
KR20070018987A (ko) | 수용체 gpr86의 용도 | |
AU2017250779A1 (en) | Methods for identifying modulators of GPR92 | |
JP2003528634A (ja) | 単離ヒトgタンパク質共役受容体、ヒトgpcrタンパク質をコード化している核酸分子、及びそれらの使用 | |
JP2003530834A (ja) | 単離した癌原遺伝子サブファミリーに属するヒトgタンパク質共役受容体、ヒトgpcrタンパク質をコード化している核酸分子、及びそれらの使用 | |
Deng | Department of Cell Physiology | |
Bredendiek | Analysis of the gustatory receptor-mediated signaling cascade in Drosophila | |
Goolam | G-protein coupling & subunit requirements in Ca2+ signalling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170303 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180306 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180730 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181226 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6461901 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |